Company Information
Bio-Gate AG
Neumeyerstrasse 28-34
90411 Nuernberg
Germany
Phone: +49 (0) 911 / 47 75 23 – 100
info@bio-gate.de
www.bio-gate.de
Press contact
Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Phone: +49 (0) 6172 807309
Mobile: +49 (0)152 34221966
Vector graphicCompany Information
Bio-Gate AG
Neumeyerstrasse 28-34
90411 Nuernberg
Germany
Phone: +49 (0) 911 / 47 75 23 – 100
info@bio-gate.de
www.bio-gate.de
Press contact
Gerd Rückel
rikutis consulting
gr@rikutis.de
presse@bio-gate.de
Phone: +49 (0) 6172 807309
Mobile: +49 (0)152 34221966
About Bio-Gate AG
Bio-Gate AG is technology health company and is one of the world's leading providers of innovative technologies and individual solutions for health and hygiene, which can make living together safer, more carefree and healthier and improve the well-being of every individual. Bio-Gate specializes in providing materials and surfaces with antiviral and antimicrobial properties. Bio-Gate AG refines materials and products, especially in the field of medical technology, such as the coating of implants or wound dressings. In addition, Bio-Gate technologies are used to uniquely enhance topical wound care products, skincare and cosmetics, consumer and industrial products such as paints and varnishes and antimicrobial plastics.
This publication constitutes neither an offer to sell nor an invitation to buy securities. The shares in Bio-Gate AG (the "Shares") may not be offered or sold in the United States or to or for the account or benefit of "U.S. persons" (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities Act")). The securities have already been sold.
Publications
Bio-Gate: Update on the HIPrevision clinical trial for HyProtect™-coated hip revision implants
Published on
Study protocol published in the internationally recognized peer-reviewed journal Trials (Springer Nature/BMC) Multicenter, randomized controlled trial at 10 centers in Germany, Poland, and Spain involving over 200 patients Further step in the clinical development of HyProtect™-coated revision implants Nuremberg, Germany, June 23, 2026 – Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative healthcare technologies, provides an update on the current status of the clinical development of the HyProtect™ coating for orthopedic implants: Following the completion of the pilot phase, the comprehensive main clinical trial has now commenced. The project – conducted in collaboration with a project partner and initially announced in December 2024 – is on track to reach the next milestone toward CE approval of HyProtect™-coated revision implants.
Bio-Gate strengthens its presence in North America with increased sales of animal care products to veterinarians and pet owners
Published on
/INS . Product launch of new animal care products at the end of April at the North American Veterinary Dermatology Forum (NAVDF) Multiplier effect through professional audience throughout North America Number of Bio-Gate customers in North America increased Nuremberg/Bremen, April 24, 2025 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative healthcare technologies, has made a dynamic start to the 2025 financial year in the Veterinary business segment and has further expanded its presence in North America. Newly developed veterinary products for skin, ear and wound care are being launched on the North American market via a global provider of specialty animal care products. Production and delivery are handled by Bio-Gate AG, which now has an even greater share of the value chain thanks to the expansion of manufacturing capacity in recent years.
Bio-Gate offers effective infection prevention in human medicine with HyProtectTM technology
Published on
/INS . Project partner launches study for CE approval of implants coated with HyProtect TM Unique selling proposition due to extremely low infection rate Prevention of implant-associated infections HyProtect TM technology is able to solve prevalent and recurring problems in the field of infection prevention in human medicine
Bio-Gate AG signs LOI with North American medical device manufacturer for trauma implants
Published on
/INS. Nuremberg/Bremen, August 2, 2023 - Bio-Gate AG (ISIN DE000BGAG981), a leading provider of innovative technologies and individual solutions for health and hygiene, has concluded a preliminary agreement (LOI, Letter-of-Intent) with a North American medical device manufacturer focusing on the trauma sector. The medical device manufacturer intends to use Bio-Gate's "HyProtect TM " coating process for its own implants in human medicine following the FDA approval process.
Bio-Gate and OSSIS expand into additional international markets with HyProtect™ Coatings on Compassionate Care implants.
Published on
Stronger and expanded international market access of OSSIS after acquisition by Zimmer Biomet Increased awareness of HyProtect™ coatings Increased volume of HyProtect™ coated implants